Peer review reports
From: Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Original Submission | ||
---|---|---|
24 Feb 2021 | Submitted | Original manuscript |
Resubmission - Version 2 | ||
Submitted | Manuscript version 2 | |
21 Mar 2021 | Reviewed | Reviewer Report - Yasuhiro Kondoh |
31 Mar 2021 | Reviewed | Reviewer Report |
10 May 2021 | Author responded | Author comments - Ulrike Schmid |
Resubmission - Version 3 | ||
10 May 2021 | Submitted | Manuscript version 3 |
12 May 2021 | Author responded | Author comments - Ulrike Schmid |
Resubmission - Version 4 | ||
12 May 2021 | Submitted | Manuscript version 4 |
14 May 2021 | Author responded | Author comments - Ulrike Schmid |
Resubmission - Version 5 | ||
14 May 2021 | Submitted | Manuscript version 5 |
Publishing | ||
14 Jun 2021 | Editorially accepted | |
21 Jul 2021 | Article published | 10.1186/s12890-021-01598-0 |